On 28 October 2022 at 11:00 a.m. an Extraordinary General Meeting was held in Scandion Oncology A/S (the "Company").
All proposals were adopted in accordance with the notice.
The full minutes of the extraordinary general meeting are attached to this notice.
The agenda of the extraordinary general meeting was as follows:
|For further information, please contact:Johnny Stilou, Acting CEO & CFOPhone: +45 2960 3532E-mail: firstname.lastname@example.org
|The information was provided by the contact person above for publication on 28 October 2022 at 12.15 CET.
|Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.
|Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are related to cancer drug resistance. Our medicines could be relevant in several cancers and makes both our medical and commercial potential significant.
|Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL).
|Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at email@example.com or +46 (0) 40 200 250.